US · Healthcare

Hangzhou Tigermed Consulting Co. Ltd (HNGZY)

Diagnostics & Research

Hangzhou Tigermed Consulting Co. Ltd (HNGZY) is listed on US in the Healthcare sector. Industry: Diagnostics & Research. As of 2026-05-23, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for HNGZY

P/E ratio

18.00

Hangzhou Tigermed Consulting Co. Ltd (HNGZY) — FAQ

What is HNGZY's P/E ratio?

The price-to-earnings (P/E) ratio for Hangzhou Tigermed Consulting Co. Ltd (HNGZY) is 18.00 (data as of 2026-05-23).

Does Hangzhou Tigermed Consulting Co. Ltd pay a dividend?

Dividend yield is not available in the current snapshot for Hangzhou Tigermed Consulting Co. Ltd (HNGZY). Check the MyAverix Finance app for the latest dividend data.

What sector is Hangzhou Tigermed Consulting Co. Ltd in?

Hangzhou Tigermed Consulting Co. Ltd (HNGZY) is classified in the Healthcare sector (Diagnostics & Research industry).

What exchange is HNGZY listed on?

HNGZY is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)